Sign in Get started
Dealert› Deals› Bio Therapeutic Drugs
Niche · Bio Therapeutic Drugs

Recent Bio Therapeutic Drugs M&A deals

Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.

Create a free account Browse other slices
Deals in this slice
822
Public & account-only records combined
Year range
2026
Across the visible recent transactions
Shown below
10
Up to 10 recent records, newest first
Account benefit
Full
All records, filters & exports
Recent transactions

Public snapshots in Bio Therapeutic Drugs

Target Buyer / Investor Sector Geo Transaction size EV / EBITDA
Crinetics Pharmaceuticals Vertex Pharmaceuticals Bio Therapeutic Drugs $10,000M n/m
Merida Biosciences Eli Lilly Bio Therapeutic Drugs $2,880M n/m
Nuvalent GSK Bio Therapeutic Drugs $10,600M 38× – 40×
Alesta Therapeutics BioMarin Pharmaceutical Inc. Bio Therapeutic Drugs $85.0M – $115M n/m
Neurona Therapeutics UCB Bio Therapeutic Drugs $47.2M – $63.8M n/m
Merida Biosciences Eli Lilly and Co. Bio Therapeutic Drugs $2,875M n/m
Kelonia Therapeutics Eli Lilly Bio Therapeutic Drugs $7,000M n/m
Nuvalent, Apogee Therapeutics GlaxoSmithKline (GSK), AbbVie Bio Therapeutic Drugs $10,750M n/m
Fulcrum Therapeutics Slate Medicines Bio Therapeutic Drugs $245M n/m
Fulcrum Therapeutics, Inc. Slate Medicines, Inc. Bio Therapeutic Drugs $245M n/m
Showing 10 of 822 records in this slice. Create a free account for the full view.
Valuations

Valuation multiples in Bio Therapeutic Drugs

Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.

Mature companies

EV / EBITDA

8.0×
1
9.0×
2
9.5×
1
10.0×
2
11.5×
1
12.5×
2
13.0×
1
14.0×
1
14.5×
2
15.0×
2
15.5×
3
16.0×
1
17.0×
3
17.5×
2
18.0×
2
18.5×
2
20.0×
3
20.5×
1
21.0×
2
22.0×
3
22.5×
2
23.5×
2
24.0×
1
24.5×
1
25.0×
3
26.0×
2
26.5×
1
27.0×
1
27.5×
1
28.5×
1
29.0×
2
29.5×
1
30.0×
2
31.0×
1
32.0×
1
32.5×
1
33.0×
2
33.5×
2
34.0×
2
35.0×
1
35.5×
1
36.0×
3
36.5×
2
37.0×
1
37.5×
1
38.0×
3
39.0×
1
40.0×
4
41.0×
1
42.0×
1
42.5×
5
45.0×
1
45.5×
1
46.0×
1
47.5×
3
48.0×
2
48.5×
1
Mean
33.49×
Median
31.71×
P25
20.00×
P75
42.52×
P90
57.14×

EV / EBIT

12.0×
1
12.5×
2
13.5×
1
14.5×
1
15.5×
1
16.0×
2
16.5×
1
17.0×
1
18.0×
1
20.0×
1
20.5×
2
21.0×
1
21.5×
2
22.0×
1
22.5×
1
23.5×
1
25.0×
1
25.5×
4
26.0×
2
26.5×
1
27.0×
1
28.0×
1
28.5×
2
29.0×
1
30.0×
2
31.0×
1
33.5×
1
34.0×
1
35.0×
3
35.5×
1
36.0×
1
36.5×
2
37.5×
2
41.0×
1
41.5×
1
42.0×
2
42.5×
4
43.0×
1
45.5×
1
46.0×
1
47.5×
2
48.5×
3
Mean
44.83×
Median
42.86×
P25
26.39×
P75
60.77×
P90
73.68×

EV / Revenue

2.0×
2
2.3×
2
2.5×
2
2.8×
2
3.0×
1
3.5×
3
3.8×
2
4.0×
5
4.3×
5
4.5×
1
4.8×
1
5.0×
3
5.3×
2
5.5×
3
5.8×
2
6.0×
1
6.3×
2
7.0×
2
7.3×
1
7.5×
4
7.8×
1
8.0×
2
8.3×
2
8.5×
1
8.8×
1
9.0×
1
9.3×
2
9.5×
2
10.3×
2
10.5×
1
11.0×
1
11.5×
3
11.8×
1
12.0×
3
12.3×
1
12.5×
4
12.8×
1
13.0×
1
13.3×
1
13.5×
1
14.3×
2
14.5×
2
14.8×
1
15.0×
4
16.0×
5
16.3×
1
16.5×
1
16.8×
2
17.0×
3
17.5×
1
18.3×
1
18.5×
1
18.8×
2
19.0×
4
20.0×
4
20.5×
1
20.8×
1
21.0×
2
21.3×
2
22.0×
2
22.8×
3
23.5×
1
24.0×
4
24.3×
1
25.0×
1
26.5×
1
27.3×
1
27.5×
2
28.0×
1
28.3×
1
28.8×
1
Mean
14.38×
Median
12.73×
P25
6.20×
P75
20.00×
P90
27.36×
Early-stage & growth companies

EV / Revenue

9.5×
4
10.0×
3
10.3×
3
10.5×
1
10.8×
1
11.0×
2
11.3×
2
11.5×
1
11.8×
3
12.0×
4
12.5×
4
13.0×
5
13.3×
4
13.5×
4
14.0×
7
14.3×
1
15.0×
3
15.3×
5
15.8×
4
16.0×
6
16.3×
8
16.5×
2
16.8×
4
17.0×
8
17.3×
1
17.5×
2
17.8×
2
18.0×
2
18.3×
5
18.5×
5
18.8×
12
19.0×
13
20.0×
23
21.0×
2
21.3×
8
21.5×
3
21.8×
1
22.0×
3
22.3×
1
22.5×
3
22.8×
11
23.0×
4
23.3×
2
23.5×
3
24.0×
7
24.3×
4
24.5×
2
24.8×
1
25.0×
4
26.0×
3
26.3×
1
26.5×
3
27.0×
1
27.3×
2
27.5×
8
28.0×
5
28.3×
4
28.5×
5
29.0×
3
29.3×
1
29.5×
1
Mean
25.41×
Median
23.12×
P25
18.18×
P75
32.00×
P90
40.00×

Looking at a different slice?

Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.

Browse the directory Create a free account